Fusion Pharmaceuticals Inc. (FUSN)
- Previous Close
21.40 - Open
21.43 - Bid 15.39 x 200
- Ask 27.36 x 200
- Day's Range
21.35 - 21.43 - 52 Week Range
2.31 - 21.55 - Volume
367,468 - Avg. Volume
2,160,341 - Market Cap (intraday)
1.816B - Beta (5Y Monthly) -0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-1.45 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.67
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.
www.fusionpharma.comRecent News: FUSN
Performance Overview: FUSN
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FUSN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FUSN
Valuation Measures
Market Cap
1.82B
Enterprise Value
1.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
678.96
Price/Book (mrq)
8.16
Enterprise Value/Revenue
789.57
Enterprise Value/EBITDA
-18.64
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.57%
Return on Equity (ttm)
-49.33%
Revenue (ttm)
2.07M
Net Income Avi to Common (ttm)
-94.9M
Diluted EPS (ttm)
-1.45
Balance Sheet and Cash Flow
Total Cash (mrq)
233.61M
Total Debt/Equity (mrq)
22.62%
Levered Free Cash Flow (ttm)
-58.58M